孟鲁司特治疗呼吸道变应性疾病的研究进展  

Advances in the treatment of respiratory allergic diseases by montelukast

作　　者：陈若瑜 宁博涵 彭华[1] CHEN Ruo-yu;NING Bo-han;PENG Hua(Department of Otorhinolaryngology,General Hospital of Southern Theater Command,PLA,Guangzhou 510010,Guangdong,China)

机构地区：[1]南部战区总医院(原广州军区总医院)耳鼻喉科

出　　处：《医学研究生学报》2019年第9期988-993,共6页Journal of Medical Postgraduates

基　　金：广东省自然科学基金(2018A0303130338)

摘　　要：呼吸道变应性疾病以气道慢性炎症反应为主要特征。白三烯拮抗剂因其在过敏性炎症中突出的疗效及安全性,而被推荐与鼻用糖皮质激素、抗组胺药一样,同为治疗呼吸道变应性疾病的一线用药。文章主要介绍白三烯拮抗剂的代表性药物孟鲁司特在治疗变应性鼻炎、支气管哮喘、咳嗽变异性哮喘、嗜酸性粒细胞性支气管炎等疾病的临床应用,旨在进一步探究白三烯拮抗剂孟鲁司特在呼吸道过敏性炎症中的应用优势和前景。Airway allergic diseases are characterized by chronic inflammatory responses in airways. Leukotriene antagonists have been recently recommended as the first-line medication for respiratory allergic diseases,along with nasal glucocorticoids and antihistamines,due to their prominent efficacy and safety in allergic inflammation. This review summarized the clinical application of Montelukast,the representative drug of leukotriene antagonists,to treat allergic rhinitis,bronchial asthma,cough variant asthma,eosinophilia bronchitis and other diseases,in order to further explore the advantages and prospect of Montelukast in the application of airway allergic inflammation.

关 键 词：孟鲁司特 变应性鼻炎 支气管哮喘 咳嗽变异性哮喘 嗜酸性粒细胞性支气管炎 

分 类 号：R56[医药卫生—呼吸系统]